Healthcare / Medical Instruments & SuppliesKuala Lumpur
$0.32
-0.00 (-1.56%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-689.6M · quality 68.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
23/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$963M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-3.9%
↓Gross Margin
N/A
•Debt/Equity
0.04
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-33.7%
FCF CAGR
—
FCF margin
-46.1%
FCF / Net income
2.25x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $781.9M · net income $-160.4M · FCF $-360.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $781.9M | $781.9M | $646.2M | $821.1M | $2.69B |
| Net Income | $-160.4M | $-160.4M | $-175.6M | $-140.9M | $718.9M |
| EBITDA | $-202.7M | $-202.7M | $-174.3M | $-96.9M | $1.14B |
| EPS | -0.05 | -0.05 | -0.06 | -0.04 | 0.23 |
| Gross Margin | — | — | 18.2% | 18.4% | 57.7% |
| Operating Margin | -32.1% | -32.1% | -37.4% | -17.3% | 42.4% |
| Net Margin | -20.5% | -20.5% | -27.2% | -17.2% | 26.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.04 | 0.04 | 0.03 | 0.02 | 0.05 |
| Current Ratio | 2.95 | 2.95 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-360.4M | $-360.4M | $-775.9M | $-689.6M | $-105.0M |
| Returns | |||||
| ROE | -3.9% | -3.9% | -3.9% | -3.1% | 14.8% |
| Valuation | |||||
| P/E | — | — | — | — | 3.03 |
| EV/EBITDA | — | — | — | — | -0.54 |
| P/B | 0.24 | 0.24 | 0.54 | 0.47 | 0.45 |
| Growth & Yield | |||||
| Revenue Growth | 21.0% | 21.0% | -21.3% | -69.4% | — |
| EPS Growth | 16.5% | 16.5% | -26.5% | -119.6% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-55.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.06 → -0.05
Residual
-55.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.